Logo of the Clinical Department of Hematology at Hannover Medical School.

MPN focus center

 

Management: Prof. Dr. med. Florian Heidel & PD Dr. med. Susanne Isfort

Lead GSG-MPN registry location Hannover: PD Dr. med. Susanne Isfort

 

Myeloproliferative neoplasms

Image of several blood platelets indicating a bloodstream.

Myeloproliferative neoplasms - MPNs - are a group of rare malignant blood cancers. Common forms of MPN include essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and chronic myeloid leukemia (CML).

Patient information on these diseases can be found on the homepage of the "German Study Group for Myeloproliferative Neoplasias (GSG-MPN)" under the heading "Information".


Clinical portfolio

  • Second opinions for initial diagnosis and in the course of treatment
  • Advice on readjusting or changing MPN medication
  • MPN diagnostics (clinical diagnostics, cytology, molecular diagnostics, coagulation diagnostics)
  • Pregnancies with MPN and CML (MPN adjustment, coagulation, advice for high-risk pregnant women)
  • Advice on indication and implementation of allogeneic stem cell transplantation
  • Coagulation disorders in MPN, severe thrombosis and bleeding
  • Advice on clinical trials and newly approved drugs
  • Opportunity to participate in the MPN register of the German MPN Study Group (GSG-MPN)
  • Rare MPN diseases (e.g. CNL) and unclear myeloproliferation (in case of suspicion)

 

Team of the MPN Focus Center

Prof. Dr. med. Florian Heidel

Head of MPN Center

Spokesperson MPN Study Group DE

PD Dr. med. Susanne Isfort

Deputy Head of MPN Center

Focus on small studies

Dr. med. Viktoria Panagiota

Focus on transplantation

Focus on cell therapy

Prof. Dr. med. Andreas Tiede

Head of Hemostaseology

 

Consultation hours, studies & additional information

DFG Research Unit 5659 "TARGET-MPN"

TARgetinG disease pErsisTence and progression of MyeloProliferative Neoplasms

Speaker: Prof. Dr. Florian Heidel

As, so far, no curative treatment for MPNs exists, the DFG Research Unit 5659 aims to unravel the molecular mechanisms of disease persistence and progression in order to develop novel targeted therapies. For this, the Research Unit investigates cell-intrinsic and -extrinsic aspects of MPN disease biology to understand yet unknown aspects of MPN persistence and progression, including the genetic and epigenetic control of gene expression, the impact of translational and post-translational protein modifications on cell-signaling as well as the role of the microenvironment, inflammation and the immune system. By this, the Research Unit aims to answer questions beyond the current understanding of MPN disease biology which might ultimately allow for the development of targeted therapies to eradicate MPN clones. Central questions the research unit aims to target are:

  • How can the disease status be defined beyond description of the genetic (mutational) state?
  • Are changes in or evolution of the epigenetic or the signaling landscape detectable in the absence of novel mutations?
  • Are common functional dependencies detectable in genetically diverse MPN cells?
  • How does the bone marrow microenvironment impact disease persistence and evolution in MPN?

Additional Information on the research unit can be found under www.for-5659.com.

Cooperations

German MPN Study Group German Chronic Myeloid Leukemia (CML) Study Group Genome Network Hematology MPN Advocates Network MPN network

Self-help initiative for people with myeloproliferative neoplasia (MPN) and their relatives

 MPN Research Foundation

founded by patients for patients and a catalyst for research funding
in the search for new treatments